This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Abraxane / Protein-Bound Paclitaxel Nanoparticle Therapy

Abraxane (Protein-Bound Paclitaxel Nanoparticle Therapy) is a chemotherapy treatment that uses tiny albumin-bound nanoparticles to deliver paclitaxel directly to tumors more efficiently than conventional formulations. It is commonly used for breast, pancreatic, and non-small cell lung cancers. By eliminating certain solvents used in traditional paclitaxel, Abraxane may reduce some side effects while improving drug delivery and treatment effectiveness.

Doctors

Dr. Patrick Soon-Shiong

doctor, surgeon | Abraxis BioScience, ANKTIVA, Cancer MoonShot 2020 / Cancer Breakthroughs 2020, Chan Soon-Shiong Family Foundation, Chan Soon-Shiong Institute for Medicine, Chan Soon-Shiong Institute of Molecular Medicine, ImmunityBio, Los Angeles Times, NantHealth, NantKwest, NantOmics, NantWorks

South African-born American surgeon, billionaire biotech entrepreneur, inventor of Abraxane, founder/executive of Immunity Bio/Nant companies, and developer/promoter of ANKTIVA/NANT Cancer Vaccine immunotherapy platforms. Patrick Soon-Shiong is a physician and biotechnology entrepreneur associated with cancer immunotherapy, including immune activation and natural killer cell-related approaches. Patrick Soon-Shiong, M. D.
All Protocols